Johnson & Johnson (NYSE:JNJ) Stock Position Raised by Ropes Wealth Advisors LLC

Ropes Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.1% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 57,909 shares of the company’s stock after acquiring an additional 616 shares during the period. Johnson & Johnson accounts for 2.0% of Ropes Wealth Advisors LLC’s portfolio, making the stock its 9th biggest position. Ropes Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $9,460,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. RKL Wealth Management LLC lifted its holdings in Johnson & Johnson by 2.1% during the 2nd quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock worth $8,562,000 after buying an additional 1,010 shares during the last quarter. Geller Advisors LLC raised its position in shares of Johnson & Johnson by 7.5% during the 2nd quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock valued at $1,644,000 after acquiring an additional 648 shares in the last quarter. Simon Quick Advisors LLC lifted its stake in Johnson & Johnson by 296.9% during the second quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock worth $1,495,000 after purchasing an additional 6,537 shares during the last quarter. Lokken Investment Group LLC boosted its holdings in Johnson & Johnson by 1.6% in the second quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock worth $2,302,000 after purchasing an additional 201 shares during the period. Finally, Keebeck Alpha LP raised its holdings in shares of Johnson & Johnson by 13.4% during the second quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock worth $788,000 after purchasing an additional 525 shares during the period. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.74 on Monday. The firm’s 50-day simple moving average is $176.14 and its 200 day simple moving average is $171.20. The stock has a market cap of $441.17 billion, a P/E ratio of 23.50, a P/E/G ratio of 3.19 and a beta of 0.56. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.68%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Insider Activity

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares in the company, valued at $6,869,966.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Ashley Mcevoy sold 73,323 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the transaction, the executive vice president now directly owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The disclosure for this sale can be found here. Insiders sold 233,611 shares of company stock worth $40,960,735 over the last three months. Corporate insiders own 0.35% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on JNJ. Barclays started coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective for the company. Morgan Stanley lowered their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. SVB Leerink reduced their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday. Raymond James dropped their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Finally, Bank of America reduced their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $181.75.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.